Longitudinal Study of Quality of Life and Activity in Systemic Lupus Erythematosus

Status

Completed

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01904812

Acronym

EQUAL

Enrollment

356

Registered

2013-07-22

Start date

2011-12-01

Completion date

2015-05-01

Last updated

2026-03-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lupus Erythematosus

Brief summary

Systemic lupus erythematosus is a complex disease whose evaluation in everyday practice and in clinical research requires several aspects to be taken into account, in particular the impact of disease activity on quality of life. To date, the effect of systemic lupus on quality of life has only been described using generic questionnaires. Among the specific questionnaires for systemic lupus, the LupusQol, which has been validated in French, shows interesting psychometric properties. The determinants of quality of life specifically related to the disease are still unknown and could be studied using a longitudinal cohort thanks to the French version of the LupusQol.

Interventions

OTHERQuestionnaire about quality of life and satisfaction

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

HEALTH_SERVICES_RESEARCH

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* \- Patients meeting ACR 1997 classification criteria for systemic lupus erythematosus. * Patients able to understand written and spoken French. * Patients aged from 18 to 75 years * Patients who have received written and oral information about the research.

Exclusion criteria

* \- Patients aged less than 18 years * Patients aged more than 75 years * Severe mental retardation Any impairment of abilities to understand that make self-evaluation impossible

Design outcomes

Primary

Measure	Time frame	Description
data for quality of life and satisfaction	participants will be followed for the duration of hospital stay, an expected average of 3 months	Quality of life and satisfaction will be evaluate by questionnaire as Questionnaire SLEQOL, QUESTIONNAIRE LUPUSQOL, QUESTIONNAIRE MFI-20

Secondary

Measure	Time frame	Description
Clinical data	participants will be followed for the duration of hospital stay, an expected average of 3 months	Question about any recent hospitalization pregnancy contraception Compliance score of Girerd Fatigue score MFI-20 tobacco consumption Score of CES-D depression Score stress response WCC

Countries

France

Contacts

PRINCIPAL_INVESTIGATORJean-François BESANCENOT

CHU Dijon - Department of Internal Medicine and Systemic Diseases

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 13, 2026